Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MONOPOLY dupilumab biomarker study in adult CRSwNP
NL-OMON54163Phase 4Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Jan 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dupilumab in chronic rhinosinusitis with nasal polyps (CRSwNP), sponsored by Amsterdam University Medical Center. Primary endpoint: Biomarker prediction of dupilumab response. Started Jan 2021; status: recruiting.
02
Drugs
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on NL-OMON54163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54163.